Two New Promising COVID-19 Drugs – Analysis and Questions

[Este artículo está disponible en español. La traducción al español apareció por primera vez en la revista Pensar.] The COVID-19 pandemic isn’t over yet. Despite the success of vaccines, people continue to get the disease. Most cases are in the unvaccinated, but even those who have been fully vaccinated can have “breakthrough” infections. Relief appears to

Dos nuevos fármacos prometedores contra el COVID-19: análisis y preguntas

[This article is also available in English. Thanks to Pensar for the Spanish translation.] La pandemia del COVID-19 aún no ha terminado. A pesar del éxito de las vacunas, las personas continúan contrayendo la enfermedad. La mayoría de los casos corresponden a personas no vacunadas, pero incluso aquellas que han sido vacunadas por completo pueden

Reducing the Risk of Adverse Drug Events

Critics of mainstream medicine often point to the dangers of drugs. I previously wrote about “Death by Medicine,” where I explained the fallacy of fixating on harmful effects of drugs without putting them into perspective with all the good drugs do. Yes, patients have died from severe allergic reactions to penicillin, but penicillin has also

All Medicines Are Poison!

That’s the title of a new book  by Melvin H. Kirschner, M.D. When I first saw the title, I expected a polemic against conventional medicine. The first line of the Preface reassured me: “Everything we do has a risk-benefit ratio.” Dr. Kirschner took the title from his first pharmacology lecture in medical school. The professor

Polypharmacy – Is It Evidence-Based?

Polypharmacy essentially means taking too many pills. It’s a real problem, especially in the elderly. A family doctor gives an elderly patient one pill for diabetes, another for high blood pressure, and another to lower cholesterol. The patient sees a rheumatologist for his arthritis and gets arthritis pills. Then he sees a psychiatrist for depression

Scroll to top